Cargando…
US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817401/ https://www.ncbi.nlm.nih.gov/pubmed/33516602 http://dx.doi.org/10.1016/j.vaccine.2021.01.050 |
| _version_ | 1783638629135941632 |
|---|---|
| author | Dal-Ré, Rafael |
| author_facet | Dal-Ré, Rafael |
| author_sort | Dal-Ré, Rafael |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7817401 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78174012021-01-21 US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine Dal-Ré, Rafael Vaccine Commentary Elsevier Ltd. 2021-02-22 2021-01-20 /pmc/articles/PMC7817401/ /pubmed/33516602 http://dx.doi.org/10.1016/j.vaccine.2021.01.050 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Commentary Dal-Ré, Rafael US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine |
| title | US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine |
| title_full | US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine |
| title_fullStr | US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine |
| title_full_unstemmed | US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine |
| title_short | US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine |
| title_sort | us fda erratic approach to placebo-controlled trials after issuing an emergency use authorization for a covid-19 vaccine |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817401/ https://www.ncbi.nlm.nih.gov/pubmed/33516602 http://dx.doi.org/10.1016/j.vaccine.2021.01.050 |
| work_keys_str_mv | AT dalrerafael usfdaerraticapproachtoplacebocontrolledtrialsafterissuinganemergencyuseauthorizationforacovid19vaccine |